NCT07150767 2025-12-02A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast CancerBeijing Bio-Targeting Therapeutics Technology Co., LtdPhase 1 Withdrawn